Product Description
DP-R202 is a new sarpogrelate hydrochloride product with an improved dosage regimen compared with the agent in current use.
Mechanisms of Action: 5-HT2A Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Alvogen
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Peripheral Arterial Disease|Peripheral Vascular Diseases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| DAVICI | P3 |
Completed |
Peripheral Vascular Diseases|Peripheral Arterial Disease |
2014-04-01 |
|
| DP-SACL-I-003 | P1 |
Completed |
Healthy Volunteers |
2011-08-01 |
|
| DP-SACL-I-002 | P1 |
Completed |
Healthy Volunteers |
2011-07-01 |
|
| DP-SACL-I-001 | P1 |
Completed |
Healthy Volunteers |
2011-02-01 |